Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422145 | 0.93 | GPR119 (0.52) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL13598276 | 0.92 | SPHK2 (0.53) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL4416490 | 0.92 | GPR119 (0.52) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL4412788 | 0.91 | GPR119 (0.55) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL13598272 | 0.91 | GPR119 (0.51) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL4414097 | 0.90 | GPR119 (0.52) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL13598280 | 0.90 | GPR119 (0.51) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL13598273 | 0.90 | GPR119 (0.51) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL4419139 | 0.90 | GPR119 (0.54) | GPR119HDAC4KDM4EPKMHDAC6 | |
| SCHEMBL4415710 | 0.89 | GPR119 (0.50) | GPR119HDAC4KDM4EPKMHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885HDAC4 2550/4885KDM4E 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.